Infectious Disease Biopharmaceuticals

SINOVAC BIOTECH LTD

Sinovac Bioscience Board Maintains Control Despite Shareholder Activism

Sinovac Bioscience Holds First Board Meeting to Elect New Chairman

SINOVAC Board Rejects SAIF's Call for a Special Meeting of Shareholders

SinoVac Urges Shareholders to Reject Controversial Proposals

Legal Dispute Arises Over Shareholder Dividend Controversy at Sinovac

US Court Bans 1Globe and Li Jiaqiang from Issuing Misleading Statements

SAIF Partners Calls for Board Reform at Sinovac

Sinovac Bioscience Holds Special Meeting to Discuss Board Composition

Sinovac Bioscience Shareholder Activism Votes Against Board Proposal

SAIF Partners Criticizes Sinovac's Board and Nominates Candidates

Sinovac's Board Secures Legal Victory and Plans Special Dividend

SINOVAC Board Urges Shareholders to Reject Special Proposal

Sinovac Biotech Announces Special Cash Dividend Of $19 Per Share And New Dividend Policy

Sinovac BioTech Shareholder Activism: Opponents Aim to Oust Current Board

Sinovac Biotech Ltd Board Rejects Partial Tender Offer

A SPAC III Acquisition

PicoCELA

Davis Commodities

Society Pass

ECD Automotive Design

Gauzy

Bristol-Myers Squibb Company

A SPAC III ACQUISITION CORP. COM NPV CL A (SUBS/RTS)02/01/2026

Paranovus ENT Tech

Cue BioPharma

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap